Ensitrelvir

DB18834ApprovedInvestigationalSmall molecule

Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).

Chemical structure of Ensitrelvir
Mechanism
Curator reviewed
Primary indication
Ensitrelvir is indicated for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19.Curator reviewed · 1 structured indication
Formula / weight
C22H17ClF3N9O2 · 531.88 g/mol (avg)
First approval
United States, 2026
Code names
S-217622
Brand names
  • Xocova 5-day

Resolves to

Compound
UNIIPX665RAA3HCAS2647530-73-0ChEMBLCHEMBL5183847
Clinical / RWD
RxNorm2745988ATCJ05AE16
Structure
InChIKeyQMPBBNUOBOFBFS-UHFFFAOYSA-NSMILESCN1C=NC(CN2C(=O)NC(=NC3=CC4=CN(C)N=C4C=C3Cl)N(CC3=CC(F)=C(F)C=C3F)C2=O)=N1
Targets
P0DTD1rep
Transporters
P08183ABCB1

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 13 drug categories
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ensitrelvir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In